REGENXBIO Medical Chief Executes Pre-Arranged Stock Sale Amid Clinical Milestones
Steve Pakola, REGENXBIO Inc.'s Chief Medical Officer, executed a sale of 2,161 shares of common stock valued at $29,476 on July 2, 2026. The transaction was part of a Rule 10b5-1 trading plan and involved the exercise of stock options at $7.86 per share. The sale occurred as the company announces significant progress in its clinical pipeline, inclu…